Market News & Trends
Kelun-Biotech & Crescent Biopharma Announce Strategic Partnership to Develop & Commercialize Novel Oncology Therapeutics
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Crescent Biopharma, Inc. recently announced they have entered into a strategic partnership to develop and commercialize oncology therapeutics, including…
Quotient Sciences & Intrepid Labs Form Strategic Partnership to Accelerate AI-Guided Formulation Development
Quotient Sciences and Intrepid Labs recently announced a ground-breaking multi-year strategic partnership to advance the use of artificial intelligence (AI) in early drug development. Under the…
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare Inc. recently announced the US FDA has granted Fast Track designation for IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment…
Leadership Transition at Vetter: Thomas Otto Retires
Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), recently announced the retirement of its Managing Director Thomas Otto after more than 35 years…
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
Protara Therapeutics, Inc. recently announced updated interim data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or…
Evonik Names New President for the Americas Region
Evonik, one of the world’s leading specialty chemicals companies, has appointed long-time Evonik executive Elias Lacerda President of the Americas region, effective February 1, 2026.…
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer…
Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease
Vandria SA recently announced topline results from its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. VNA-318 is a first-in-class, orally…
Bayer Starts New Phase III Study with Mirena for the Treatment of Nonatypical Endometrial Hyperplasia
Bayer recently announced the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena…
NorthX Biologics Achieves Milestone GMP Certification to Manufacture Mendus’ Lead Cell Therapy Product for Acute & Chronic Myeloid Leukemias
NorthX Biologics and Mendus recently announced the successful completion of GMP manufacturing certification for Mendus’ lead cell therapy product, vididencel. This milestone marks the culmination…
Belite Bio Announces Positive Topline Results From Pivotal Global Phase 3 of Tinlarebant in Adolescents With Stargardt Disease
Belite Bio, Inc recently announced topline results from the global Phase 3 DRAGON trial of Tinlarebant, marking the first successful pivotal trial in patients with…
Croda Expands Biopharma Capabilities Through Strategic Partnership
Croda International Plc recently announced a strategic supply partnership with Amino GmbH aimed at strengthening the global availability of high purity amino acids for pharmaceutical…
Sever Pharma Solutions Appoints Linda Rebert as VP Operations
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in Controlled-Release Drug Delivery Systems for highly potent drugs, with development and manufacturing…
Bracco, Limula & University of Fribourg Join Forces to Improve Cell & Gene Therapy Manufacturing
Bracco Imaging and Limula recently announced the launch of a research and development (R&D) project in collaboration with Prof. Nicola Vannini, an expert in T-cell…
Amphista Therapeutics Announces New AMX-883 Data to be Presented & Provides a Business Progress Update
Amphista Therapeutics recently announced the presentation of new preclinical data with its lead Targeted Glue AMX-883, an orally bioavailable, potent and selective degrader of BRD9…
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics, Inc. recently announced it recently initiated dosing in its BROADEN2 Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of…
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) recently announced the University of Bonn, Germany is now actively screening patients for the Phase 3 Serenta clinical trial evaluating…
Sever Pharma Solutions Celebrates 50 years of Pharmaceutical Innovation
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release drug delivery systems for high-potent drugs, is proud to celebrate…
Azalea Therapeutics Presents New Preclinical Data Demonstrating Robust In Vivo Generation of TRAC-CAR T Cells Using Enveloped Delivery Vehicles
Azalea Therapeutics, Inc. recently announced new preclinical data demonstrating robust in vivo generation of functional TRAC-CAR T cells using its proprietary Enveloped Delivery Vehicle (EDV) technology.…
BriaCell & Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
BriaCell Therapeutics Corp. recently announced its subsidiary, BriaPro Therapeutics Corp., has initiated a research collaboration with Receptor.AI, an AI-driven drug discovery company, to design anti-cancer…
